Market capitalization | $1.30b |
Enterprise Value | $742.13m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 7.28 |
P/S ratio (TTM) P/S ratio | 12.73 |
P/B ratio (TTM) P/B ratio | 2.34 |
Revenue (TTM) Revenue | $101.95m |
EBIT (operating result TTM) EBIT | $-211.46m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
10 Analysts have issued a Day One Biopharmaceuticals Inc forecast:
10 Analysts have issued a Day One Biopharmaceuticals Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 102 102 |
-
|
|
Gross Profit | 99 99 |
21,717%
21,717%
|
|
EBITDA | -210 -210 |
11%
11%
|
EBIT (Operating Income) EBIT | -211 -211 |
12%
12%
|
Net Profit | -84 -84 |
52%
52%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Day One Biopharmaceuticals, Inc. operates as a holding company. The firm through its subsidiary develops and commercializes targeted therapies for patients of all ages with genetically defined cancers. Its products include DAY101 and pimsertib. The company was founded by Julie Grant and Samuel Blackman in November 2018 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Jeremy Bender |
Employees | 155 |
Founded | 2018 |
Website | www.dayonebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.